Zilver PTX 数据库中股腘动脉病变外周血管介入术后 12 个月健康状态反应:关注术前健康状态、合并症风险与全球设置的作用
基于 Zilver PTX 随机试验与单臂研究合并队列的 513 例股腘动脉外周血管介入患者,采用 EQ-5D 评估术前与术后 12 个月健康状态。术后 12 个月 57.9% 改善、31.4% 无变化、10.7% 恶化;颈动脉疾病史和美国入组中心与无反应相关。
要点
- 股腘动脉介入术后 12 个月,57.9% 患者健康状态改善,31.4% 无变化,10.7% 恶化。
- EQ-5D 最小临床重要差异阈值为 0.058,用于区分有反应与无反应。
- 颈动脉疾病史及美国入组中心与 12 个月健康状态无反应相关。
核心结论
- 多数股腘动脉外周血管介入患者术后健康状态改善或稳定,约四成无反应,颈动脉疾病史和美国入组中心与无反应风险最高相关。
研究设计与样本
- 二次数据分析,合并 Zilver PTX 随机试验与单臂研究中 2005 年 3 月至 2008 年 8 月接受股腘动脉外周血管介入的患者为单队列,共 513 例,平均年龄 67.8±9.2 岁,女性 25.1%,美国入组中心 17.8%、非美国 82.2%。
主要发现
- 术后 12 个月 EQ-5D 健康状态较术前改善者 57.9%、无变化者 31.4%、恶化者 10.7%。
- EQ-5D 最小临床重要差异阈值为 0.058。
- 校正治疗条件和患者特征后,颈动脉疾病史患者及美国入组中心患者更可能为 12 个月无反应者。
关键数值与推荐
- EQ-5D 最小临床重要差异阈值为 0.058,用于定义 12 个月无反应(恶化或无变化)与有反应(改善)。
- 以 EQ-5D 指数每增加 1 单位评估 12 个月健康状态,并校正治疗条件和患者特征。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tailoring resources of peripheral vascular interventions (PVIs) to those who stand to gain the most would allow for more equitable and value-based care. One way of evaluating the benefit of PVIs in patients with symptomatic peripheral artery disease is evaluating their health status and identifying predictors of health status response 12 months after the intervention. METHODS: Patients who underwent femoropopliteal PVI between March 2005 and August 2008 from the Zilver PTX randomized trial and single-arm study were combined into a single cohort for secondary data analysis. The preprocedural and 12-month health status was assessed by the EuroQol-5D-3 L (EQ-5D). First, we evaluated the 12-month EQ-5D Index (per 1-unit increase), adjusted for treatment condition and patient characteristics using a linear regression. Second, using the minimally clinically important difference threshold for the EQ-5D Index, we identified 12-month nonresponders (worsened or no change) vs responders (improved) and conducted an adjusted logistic regression model. RESULTS: A total of 513 patients were included (mean age: 67.8 ± 9.2 years; 25.1% female), with 17.8% U.S. and 82.2% non-U.S. global enrollment sites. The minimally clinically important difference for the EQ-5D was 0.058. For 12-month health status after PVI, a total of 57.9% improved, 31.4% experienced no change, and 10.7% worsened, relative to their preprocedural health status. Patients who were more likely to be nonresponders were more likely to have a history of carotid artery disease or were located at a U.S. enrolling center. CONCLUSIONS: The majority of patients reported improved or stable health status after femoral-popliteal PVI. Approximately 4 in 10 patients were nonresponders, with the highest risk for nonresponse including individuals with existing carotid disease or those undergoing PVIs in the U.S. vs non-U.S.
引用
- Smolderen KG, Romain G, Cleman J, et al. Twelve-month health status response after peripheral vascular intervention for femoropopliteal lesions using Zilver PTX databases focusing on the role of preprocedural health status, comorbid risks, and global setting. J Vasc Surg. 2024. PMID: 39214426. doi:10.1016/j.jvs.2024.08.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。